Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579589 · ClinicalTrials.gov registry record · Phase 1
The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal
A Phase 1 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03579589 is a Phase 1 study that has completed, run by Ohio State University. The registered enrollment target is 40 participants.
The verdict
NCT03579589, a Phase 1 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Patients who undergo surgery receive drugs called neuromuscular blocking agents (NMBA) that to block the activity of muscles. When the surgery is over, the block needs to be reversed. Suggammadex and neostigmine are examples of drugs that reverse blocks. This study aims to investigate if sugammadex is associated with a significantly reduced time to discharge from the operating room to the postoperative unit when compared to neostigmine.
Interventions
- DRUG Sugammadex vs Neostigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-08-15 |
| Est. Completion | 2019-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579589
The ClinicalTrials.gov registry entry for NCT03579589 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sugammadex vs Neostigmine is the first listed.
NCT03579589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03579589 about?
NCT03579589 is a clinical study titled "The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal". Patients who undergo surgery receive drugs called neuromuscular blocking agents (NMBA) that to block the activity of muscles. When the surgery is over, the block needs to be reversed. Suggammadex and neostigmine are examples of drugs that reverse blocks. This study aims to investigate if sugammadex ...
What is the current status of trial NCT03579589?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-08-15. Estimated completion is 2019-12-15.
What interventions are being tested in trial NCT03579589?
The interventions under investigation include: Sugammadex vs Neostigmine (DRUG).
Who is sponsoring clinical trial NCT03579589?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.